Filana Therapeutics
FLNA
28 hedge funds and large institutions have $9.65M invested in Filana Therapeutics in 2017 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 5 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
0.74% less ownership
Funds ownership: 36.68% → 35.94% (-0.74%)
3% less capital invested
Capital invested by funds: $9.91M → $9.65M (-$261K)
15% less funds holding
Funds holding: 33 → 28 (-5)
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$49.7K |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$31.4K |
| 3 |
GI
GAMCO Investors
Greenwich,
Connecticut
|
+$25K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$2.86K |
| 5 |
BlackRock
New York
|
+$1.43K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GF
Gabelli Funds
Rye,
New York
|
-$98K |
| 2 |
ARTA
A.R.T. Advisors
New York
|
-$50.6K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$44K |
| 4 |
First Eagle Investment Management
New York
|
-$25.5K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$14.9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GF
26
Gabelli Funds
Rye,
New York
| – | -$98K | -23,571 | Closed |
|
|
TSS
27
Two Sigma Securities
New York
| – | -$44K | -10,587 | Closed |
|
28
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$2.88K | -805 | -99% |
|
29
Acadian Asset Management
Boston,
Massachusetts
| – | -$2K | -581 | Closed |
|
30
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$25 | +7 | New |
|
FLNA Hedge Fund Activity: Q3 2017 in Review
28 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Filana Therapeutics (FLNA) for Q3 2017, worth a combined $9.65M — down 2.6% from $9.91M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of FLNA and 1 opened new positions — a net loss of 4 holders — while 8 trimmed existing stakes and 8 added.
The largest buyer was Renaissance Technologies, adding an estimated $49.7K. The largest seller was Gabelli Funds, exiting entirely with an estimated $98K sold.
- 28 institutional investors held Filana Therapeutics (FLNA) as of Q3 2017, down from 33 in Q2 2017.
- Funds reported $9.65M of Filana Therapeutics stock for Q3 2017, down 2.6% quarter-over-quarter.
- 1 fund opened new Filana Therapeutics positions in Q3 2017 and 5 closed out, a net change of -4 holders.
- The largest Filana Therapeutics buyer in Q3 2017 was Renaissance Technologies, an estimated $49.7K added.
- The largest Filana Therapeutics seller in Q3 2017 was Gabelli Funds, an estimated $98K sold.
Based on aggregated 13F filings for Q3 2017.